We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Non-Amyloid Alzheimer’s Drug Candidate Shows Promise in Clinical Study
Non-Amyloid Alzheimer’s Drug Candidate Shows Promise in Clinical Study
Axon Neuroscience’s investigational anti-tau antibody treatment for Alzheimer’s disease, AADvac1, has posted positive phase 2b results, reducing cognitive slowing by up to 30 percent and neurodegeneration by 62 percent compared to placebo in patients with biomarker-confirmed disease.